RRML - High DNAJA4 expression correlates with poor survival outcomes in breast cancer

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17

Advanced search

Top 10 downloaded articles
- December 2022 -
Downregulation of hsa-miR-4328... 5
Normality assessment, few para... 4
High DNAJA4 expression correla... 4
Setting up an own laboratory p... 4
New Para-Clinical Investigatio... 3
Genetic risk factors for throm... 3
miR-190, CDK1, MCM10 and NDC80... 3
The relationship between matri... 2
A model for calculating measur... 2
The Use of Infrared Spectrosco... 2

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 30(4)/2022 DOI:10.2478/rrlm-2022-0035

Research article

High DNAJA4 expression correlates with poor survival outcomes in breast cancer

Tolga Acun, Oya Incekara

Correspondence should be addressed to: Tolga Acun


Background: DNAJA4 (PRO1472) is a heat shock protein that has been associated with several types of cancers, including breast cancer. We aimed to reveal the protein expression, clinical outcomes, and regulatory mechanisms of DNAJA4 gene in breast cancer by employing tissue microarrays, transcriptomic datasets, and in-silico tools. Methods: DNAJA4 protein expression and its clinical implications were evaluated by immunohistochemistry assay (normals = 32; tumors = 121). RNA-seq and DNA microarray datasets were analyzed by using breast cancer gene-expression miner (Bc-GenExMiner v4.8) to estimate the survival probabilities of breast cancer patients. DNAJA4 promoter methylation level was analyzed in clinical samples by UALCAN in-silico tool (normals = 97; tumors = 793). Results: DNAJA4 protein expression is significantly high in clinical breast cancer samples compared to the normal samples (P = 0.016). High DNAJA4 mRNA expression is correlated with poor overall survival (OS), disease-free survival (DFS), and distant metastasis-free survival (DMFS) in breast cancer patients (P < 0.05). Mutations or copy number variations of DNAJA4 are uncommon in clinical samples. Reduced promoter methylation was observed in clinical breast cancer samples. Conclusion: We suggest DNAJA4 expression as a new biomarker candidate for breast cancer. Promoter hypomethylation could be an important epigenetic factor in the upregulation of DNAJA4 expression in breast cancer.

Keywords: breast cancer, survival, methylation, expression, DNAJA4

Received: 6.4.2022
Accepted: 14.9.2022
Published: 23.9.2022

  PDF Download full text PDF
(1900 KB)
  PDF Supplementary material
How to cite
Acun T, Incekara O. High DNAJA4 expression correlates with poor survival outcomes in breast cancer. Rev Romana Med Lab. 2022;30(4):369-78. DOI:10.2478/rrlm-2022-0035